Clinical Pharmacokinetics of Inhaled Drugs for Pulmonary Hypertension [0.03%]
用于治疗肺动脉高压的吸入药物的临床药代动力学
Yu Lin,Yuanqi Su,Zhongjie Cheng et al.
Yu Lin et al.
Pulmonary hypertension (PH) is a serious condition characterized by elevated blood pressure in the pulmonary arteries. Current treatment approaches mainly focus on using vasodilator agents to reduce pulmonary blood pressure and improve bloo...
Investigation of the Suitability of Utilizing Plasma Concentration as a Surrogate to Understand Lung Exposure of Inhaled Drug in Rats: Different Delivery Methods of Fluticasone Propionate [0.03%]
基于大鼠的吸入给药的不同投与方法，调查血浆浓度作为理解肺暴露药物替代指标的适用性：氟替卡松磷酸氢二钠
Po-Chang Chiang,Cornelia H Rinderknecht,Jia Liu et al.
Po-Chang Chiang et al.
This is of critical importance since many inhaled drugs are designed to have topical-only efficacy to reduce systemic side effects.
An In Vitro Dissolution Method for Inhaled Drugs Depositing in the Tracheobronchial Lung Region [0.03%]
一种测定气道肺部沉积吸入药物的体外溶出方法研究
Alexander Huang,Scott Tavernini,Dino J Farina et al.
Alexander Huang et al.
Purpose: To evaluate and develop a novel dissolution test method using tracheobronchial (TB) mimic filters for assessing the dissolution behavior of inhaled drugs targeting the tracheobronchial lung region.
Occupational Exposure of Healthcare Workers during Drug Reconstitution and Handling Tasks: a multicenter assessment at Dutch Hospital Wards [0.03%]
荷兰医院病房医护人员在药物配制和处理任务中的职业暴露：多中心评估
Roland B van den Berg,Percival Stubbs,Johanna R C Boumans-d&#x;Onofrio et al.
Roland B van den Berg et al.
Objective: This study evaluated healthcare workers' occupational exposure to inhaled drugs during drug reconstitution and handling tasks, focusing on compliance with occupational exposure limits (OELs).
Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery [0.03%]
基于生理的 translational 药代动力学建模，以预测肺部给药后人体的肺动力学变化
Haini Wen,Muhammad Waqas Sadiq,Lena E Friberg et al.
Haini Wen et al.
Predicting human lung exposure with reasonable certainty of orally inhaled drugs based on preclinical studies remains a challenge for drug development.
iBCS: 4. Application of the Inhalation Biopharmaceutics Classification System to the Development of Orally Inhaled Drug Products [0.03%]
iBCS: 4. 吸入生物药剂学分类系统在口服吸入药物产品开发中的应用
Ben Forbes,Per Bäckman,Antonio Cabal et al.
Ben Forbes et al.
As described in three prior publications, the iBCS was developed to classify inhaled drugs based on physicochemical and biorelevant product attributes in a manner that will allow formulators and discovery chemists to identify and mitigate product development risks.
The availability of drugs for stable COPD treatment in China: a cross-sectional survey [0.03%]
中国稳定期慢阻肺治疗药物的可及性横断面调查
Dongru Du,Xueru Hu,Qiunan Zuo et al.
Dongru Du et al.
Both inhaled drugs (monotherapy, double therapy and triple therapy) and oral drugs (expectorants, theophylline, antibiotics, and bacterial lysates) were included in this survey. Doctors from different hospitals completed the survey via WeChat....Most inhaled drugs did not reach an availability of 20% in primary hospitals, except for salbutamol (59.7%), tiotropium bromide (20.0%) and beclometasone/formoterol (23.1%).
A 3D Model of the Human Lung Airway for Evaluating Permeability of Inhaled Drugs [0.03%]
一种用于评估吸入药物通透性的三维人体气道模型
Shekh M Rahman,Robert M Geiger,Md Shadiqur Rashid Roni et al.
Shekh M Rahman et al.
To understand how the characterized ALI quality attributes influenced the absorption of inhaled drugs through the epithelial-endothelial barrier, we measured the permeability and epithelial intracellular concentrations of albuterol sulfate (AL), formoterol fumarate (FO), and fluticasone furoate (FL)....While the model exhibited physiologically relevant properties, its utility in estimating the permeability of inhaled drugs may be drug-specific, warranting further optimization and study.
Sara E Maloney Norcross,Leanna P K Levin,Anthony J Hickey et al.
Sara E Maloney Norcross et al.
There are multiple physiological barriers to the penetration of inhaled drugs to the epithelial surface, such as the periciliary layer mucus mesh, pulmonary macrophages, and inflammation and mucus compositional changes resulting from respiratory diseases.
Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysis [0.03%]
药物治疗慢性阻塞性肺疾病的长期增量益处在于改善生活质量而非降低死亡率：网络meta分析
Qiong Pan,Jiongzhou Sun,Shiyuan Gao et al.
Qiong Pan et al.
The efficacy of dupilumab compared with conventional inhaled drugs remains incompletely determined. This study aimed to investigate the comparative efficacy of dupilumab and conventional inhaled drugs in patients with stable COPD.
耗时 0.10366 秒，为您在
48206918
条记录里面共找到 407 篇文章 [XML]